GILD : Summary for Gilead Sciences, Inc. - Yahoo Finance

U.S. Markets closed

Gilead Sciences, Inc. (GILD)


NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
66.25+0.32 (+0.49%)
At close: 4:00PM EDT

66.25 0.00 (0.00%)
After hours: 5:08PM EDT

People also watch
CELGBIIBAMGNBMYREGN
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous Close65.93
Open66.48
Bid66.16 x 700
Ask66.25 x 200
Day's Range65.71 - 66.49
52 Week Range65.38 - 103.10
Volume7,932,743
Avg. Volume9,759,458
Market Cap86.6B
Beta0.99
PE Ratio (TTM)6.66
EPS (TTM)N/A
Earnings DateN/A
Dividend & Yield2.08 (3.12%)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Better Buy: Gilead Sciences vs. Celgene
    Motley Fool4 hours ago

    Better Buy: Gilead Sciences vs. Celgene

    These two biopharmaceutical stocks have been going in opposite directions, which has left one trading at a bargain valuation.

  • Barrons.com6 hours ago

    Gilead Sciences: Know Hope…or No Hope?

    Gilead Sciences (GILD) has been trending lower ever since the market realized that its hepatitis-C sales were only going to keep declining for a while. Gilead's dominant HIV program, which has fallen under a cloud, probably won't do it, leading some investors to conclude there's little hope for the biotech giant without a good healthy dose of M&A. Still, it's not given much credit for its pipeline. Amsterdam, the Netherlands), we have seen data and heard feedback from KOLs that further supports our view that GILD has both the greatest breadth of pipeline assets, deep knowledge of liver biology and comprehensive biomarker strategy for treatment of Non-Alcoholic Steatohepatitis (NASH), a growing disease area affecting est.

  • Zacks7 hours ago

    Is Pain Ahead for Healthcare ETFs After Weak JNJ Q1?

    Results from Johnson and Johnson could be a warning sign for other drug makers, which are scheduled to report this week and the next.